- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03631277
Indirect Pulp Treatment of Young Permanent Molars Using Photo-Activated Oral Disinfection Versus Calcium Hydroxide
Clinical and Radiographic Evaluation of Indirect Pulp Treatment of Young Permanent Molars Using Photo-Activated Oral Disinfection Versus Calcium Hydroxide: A Randomized Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Indirect pulp treatment is a procedure in which pulp exposure is prevented by preserving the carious dentin bordering the pulp and sealing the pulp with a biocompatible material. . Calcium hydroxide is the gold standard for pulp capping, it permits reparative dentin bridge formation, maintains pulp vitality, protects the pulp against harmful stimuli and has antimicrobial effect. However, several disadvantages were reported with its use over time including poor seal, lack of chemical and mechanical adhesion, poor strength, long-term solubility, enhanced degradation after acid etching and tunnel defects in the dentin bridge . The operative tradition is to remove softened dentin to eliminate infected tissue; however, it is impossible to eradicate all the micro-organisms because few will persist although all soft dentin was excavated.
Evidence suggest that for arresting caries lesions, it is not crucial to completely remove the infected dentin and that selective caries removal and composite restoration can yield better clinical results . For more conservative and effective treatment, disinfection instead of complete caries removal has been encouraged. . PAD is an advanced technology utilizing two non-toxic components, a photo-activating liquid and a LED light source that selectively target and abolish cariogenic bacteria and periodontal pathogens . The usage of PAD in caries management can eradicate residual bacteria in soft dentin, reassures rapid healing and improve the prognosis of treatment .
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Restorable lower first permanent molars with deep carious lesions
- Absence of clinical signs and symptoms of irreversible pulpitis, fistula, swelling in periodontal tissues or abnormal tooth mobility
- Absence of adverse radiographic findings
- Compliant patient/parent and (e) Absence of any systemic disease.
Exclusion Criteria:
• Previously restored teeth .
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: photo-activated oral disinfection
photo-activated oral disinfection is an advanced technology utilizing two non-toxic components, a photo-activating liquid and a LED light source that selectively target and abolish cariogenic bacteria and periodontal pathogens
|
Application of PAD solution using disposable tip with agitation of the solution for 60 seconds using a brush; Placement of the light disposable tip in center of lesion and holding it just above the surface; Activation of the red light for 60 seconds; (h)Sealing the cavity with glass ionomer and then filling with composite resin as a final restoration
Other Names:
|
|
Active Comparator: calcium hydroxide
Calcium hydroxide is the gold standard for pulp capping, it permits reparative dentin bridge formation, maintains pulp vitality, protects the pulp against harmful stimuli and has antimicrobial effect
|
calcium hydroxide( Dycal ® Dentsply Caulk )was applied using calcium hydroxide applicator followed by glass ionomer and then composite resin as a final restoration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
postoperative pain: verbal rating scale
Time Frame: 2 months
|
categorical (No pain, Mild pain, Moderate, Severe, Very Severe, Worst possible pain ).
Assessed by using verbal rating scale.
minimum value is no pain while maximum value is worst possible pain.
Higher values represent a worse outcome
|
2 months
|
|
postoperative pain: verbal rating scale
Time Frame: 6 months
|
categorical (No pain, Mild pain, Moderate, Severe, Very Severe, Worst possible pain ).
Assessed by using verbal rating scale.
minimum value is no pain while maximum value is worst possible pain.
Higher values represent a worse outcome
|
6 months
|
|
postoperative pain: verbal rating scale
Time Frame: 9 months
|
categorical (No pain, Mild pain, Moderate, Severe, Very Severe, Worst possible pain ).
Assessed by using verbal rating scale.
minimum value is no pain while maximum value is worst possible pain.
Higher values represent a worse outcome
|
9 months
|
|
postoperative pain: verbal rating scale
Time Frame: 12 months
|
categorical (No pain, Mild pain, Moderate, Severe, Very Severe, Worst possible pain ).
Assessed by using verbal rating scale.
minimum value is no pain while maximum value is worst possible pain.
Higher values represent a worse outcome.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Presence or absence of pain on percussion
Time Frame: 2,6,9 and 12 months
|
Binary outcome (Present or absent).
Assessed by tapping the tooth with the back of the mirror
|
2,6,9 and 12 months
|
|
Swelling
Time Frame: 2,6,9 and 12 months
|
Binary outcome (Present or absent).
Assessed by visual examination by the examiner
|
2,6,9 and 12 months
|
|
Sinus or fistula
Time Frame: 2,6,9 and 12 months
|
Binary outcome (Present or absent).
Assessed by visual examination by the examiner
|
2,6,9 and 12 months
|
|
Adverse radiographic findings
Time Frame: 2,6,9 and 12 months
|
Binary outcome (Present or absent).
Assessed by Digora software
|
2,6,9 and 12 months
|
|
Thickness of newly formed dentin
Time Frame: 2,6,9 and 12 months
|
using the Digora software.
Unit of measurements were mm
|
2,6,9 and 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Ahmed M Abd Alsamad, PHD, Cairo University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- pulp capping
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Deep Caries
-
Hacettepe UniversityRecruitingDeep Caries | Dentin CariesTurkey
-
Minia UniversityRecruiting
-
Cairo UniversityRecruiting
-
Cairo UniversityNot yet recruiting
-
Universidad Rey Juan CarlosRecruiting
-
Izmir Katip Celebi UniversityCompleted
-
Fayoum UniversityCompleted
-
Cairo UniversityCompleted
Clinical Trials on photo-activated oral disinfection
-
Cairo UniversityUnknown
-
Eli Lilly and CompanyCompletedSepsis | Septic ShockUnited States
-
Minia UniversityNot yet recruitingNecrotic Pulp | Immature Teeth
-
University of LjubljanaUniversity Medical Centre LjubljanaCompletedAntimicrobial Photodynamic Therapy in Patients With Periodontal Disease and Type 2 Diabetes MellitusDiabetes Mellitus, Type 2 | Periodontitis | Periodontal Diseases | Periodontal Pocket | Periodontal Attachment Loss | Periodontal Inflammation
-
Zambon SpACompleted
-
Zambon SpACompleted
-
AstraZenecaParexelCompletedChronic Obstructive Pulmonary DiseaseUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedMalaria | Severe MalariaMali
-
Orion Corporation, Orion PharmaCompletedHealthy VolunteersFinland